Targacept launches Phase II; Amylin touts blood sugar data; drug reduces craving for alcohol

> Targacept has launched a Phase II trial of a potential new therapy for ADHD. The drug targets receptors of neuronal nicotinic receptors. Report

> Amylin Pharmaceuticals released new data showing that patients taking Symlin with basal insulin lowered blood sugar levels more than a group taking rapid-acting insulin combined with basal insulin. Release

> Scientists say that an ingredient in garlic can beat MRSA. Report

> Another week, another big medical society meeting sending shock-waves--good and bad--through the pharma biz. This week, of course, it's the wrap-up of the American Diabetes Association confab. ADA report

> Lately it hasn't been a love-fest among analysts and investors and Big Pharma. A few drugmakers have won their kudos, but overall the mood has been somewhat grim. Not so today. Going contrarian, a BusinessWeek columnist touts Pfizer, and a former analyst is launching (drum roll, please) a pharma-based hedge fund. Report

> Just what Merck doesn't need: Its asthma-and-allergy med Singulair is losing ground, with new scrips down year-over-year for 13 weeks straight. Singulair report

> The FDA might finally get its $275 million in additional funding. Report

> Few disease targets are as attractive to drug developers as obesity. And few are as complex. Researchers and drug companies are routinely stumped in trying to develop a pill that can trump the body's 'guerrilla tactics' when it comes to weight loss. Obesity report

> Researchers at the University of Virginia say that an epilepsy drug--topiramate--can reduce alcoholics' craving for a drink as well as promote their overall health. Report

> So far this year a more vigilant FDA has barred seven physicians from conducting medical research work. FDA report

And Finally... Researchers at the University of Virginia say that an epilepsy drug - topiramate - can reduce alcoholics' craving for a drink as well as promote their overall health. Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.